$EMMA
Emmaus Life Sciences, Inc.

2019 Q4 Form 10-K Financial Statement

#000156459021001977 Filed on January 25, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019
Revenue $22.75M $5.760M $22.75M
YoY Change 5777.55% 17.98% 38.23%
Cost Of Revenue $1.094M $248.0K $1.094M
YoY Change 386.01% 75.89% 32.22%
Gross Profit $21.66M $5.512M $21.66M
YoY Change 13269.14% 16.26% 4337.21%
Gross Profit Margin 95.19% 95.69% 95.19%
Selling, General & Admin $23.99M $8.834M $23.99M
YoY Change 849.72% 37.9% 8.06%
% of Gross Profit 110.75% 160.27% 110.75%
Research & Development $2.183M $725.0K $2.183M
YoY Change 586.91% 55.58% 58.48%
% of Gross Profit 10.08% 13.15% 10.08%
Depreciation & Amortization $19.00K $16.00K $73.00K
YoY Change -37.09% 23.08% 19.67%
% of Gross Profit 0.09% 0.29% 0.34%
Operating Expenses $26.17M $9.559M $26.17M
YoY Change 820.34% 39.1% 9.41%
Operating Profit -$4.512M -$4.047M -$4.512M
YoY Change 68.26% 89.91% -46.63%
Interest Expense -$46.31M $8.714M $27.63M
YoY Change 202127.07% 57.72% 21.18%
% of Operating Profit
Other Income/Expense, Net -$3.109M -$22.46M -$3.109M
YoY Change -234.49%
Pretax Income -$54.68M -$18.34M -$54.68M
YoY Change 1921.82% -225.86% -24.63%
Income Tax $164.0K $56.00K $164.0K
% Of Pretax Income
Net Earnings -$54.84M -$18.39M -$54.80M
YoY Change 2206.71% -226.24% -24.5%
Net Earnings / Revenue -241.04% -319.31% -240.86%
Basic Earnings Per Share -$0.60
Diluted Earnings Per Share -$1.298M -$0.60 -$1.298M
COMMON SHARES
Basic Shares Outstanding 48.47M 45.99M 42.26M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.70M $41.19M $29.70M
YoY Change 1880.13% 1165.52% 812.47%
Cash & Equivalents $1.769M $1.326M
Short-Term Investments $27.93M $27.64M $27.93M
Other Short-Term Assets $667.0K $767.0K $1.402M
YoY Change 62.29% 298.23% 627.93%
Inventory $7.971M $7.491M $7.971M
Prepaid Expenses
Receivables $2.150M $1.982M $2.150M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $41.22M $39.98M $41.22M
YoY Change -31.99% 1038.92% 1074.19%
LONG-TERM ASSETS
Property, Plant & Equipment $151.0K $163.0K $4.625M
YoY Change -0.66% 47.11% 4074.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $13.33M $0.00 $13.33M
YoY Change
Other Assets $285.0K $427.0K $285.0K
YoY Change -29.8% 1475.65% 951.66%
Total Long-Term Assets $18.24M $18.12M $18.24M
YoY Change 24.34% 1003.77% 1011.08%
TOTAL ASSETS
Total Short-Term Assets $41.22M $39.98M $41.22M
Total Long-Term Assets $18.24M $18.12M $18.24M
Total Assets $59.46M $58.10M $59.46M
YoY Change -21.02% 1027.72% 1054.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.277M $7.400M $7.277M
YoY Change 109.95% 2033.18% 1997.72%
Accrued Expenses $3.188M $2.446M $5.212M
YoY Change 78.2% 272.02% 692.7%
Deferred Revenue
YoY Change
Short-Term Debt $793.0K $193.0K $793.0K
YoY Change
Long-Term Debt Due $13.76M $17.81M $13.76M
YoY Change 982685.71% 1370207.69% 1058284.62%
Total Short-Term Liabilities $32.83M $31.37M $32.83M
YoY Change -27.94% 2591.87% 2716.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.200M $0.00
YoY Change -100.0% 103.46% -100.0%
Other Long-Term Liabilities $33.75M $34.56M $37.68M
YoY Change -6.82% 31286.01% 34125.25%
Total Long-Term Liabilities $37.68M $39.50M $37.68M
YoY Change -28.8% 5543.52% 5283.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.83M $31.37M $32.83M
Total Long-Term Liabilities $37.68M $39.50M $37.68M
Total Liabilities $70.51M $70.35M $70.51M
YoY Change -27.3% 6120.44% 6134.77%
SHAREHOLDERS EQUITY
Retained Earnings -$226.2M -$224.9M
YoY Change 32.02%
Common Stock $215.3M $212.7M
YoY Change 43.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$11.05M -$12.17M -$11.05M
YoY Change
Total Liabilities & Shareholders Equity $59.46M $58.10M $59.46M
YoY Change -21.02% 1027.72% 1054.08%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019
OPERATING ACTIVITIES
Net Income -$54.84M -$18.39M -$54.80M
YoY Change 2206.71% -226.24% -24.5%
Depreciation, Depletion And Amortization $19.00K $16.00K $73.00K
YoY Change -37.09% 23.08% 19.67%
Cash From Operating Activities $555.0K $948.1K -$4.523M
YoY Change -131.86% -158.21% -19.72%
INVESTING ACTIVITIES
Capital Expenditures -$5.000K -$34.20K $60.00K
YoY Change 21.95% -812.5% -36.17%
Acquisitions
YoY Change
Other Investing Activities -$4.000K -$1.420M -$1.424M
YoY Change -41864.71% 364.45%
Cash From Investing Activities -$9.000K -$1.454M -$1.484M
YoY Change 119.51% 80688.89% -80.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.589M
YoY Change 573.65%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 856.0K -2.208M 3.884M
YoY Change -10053.49% -198.72% -169.64%
NET CHANGE
Cash From Operating Activities 555.0K 948.1K -4.523M
Cash From Investing Activities -9.000K -1.454M -1.484M
Cash From Financing Activities 856.0K -2.208M 3.884M
Net Change In Cash 1.402M -2.714M -2.136M
YoY Change -179.89% -548.03% -88.55%
FREE CASH FLOW
Cash From Operating Activities $555.0K $948.1K -$4.523M
Capital Expenditures -$5.000K -$34.20K $60.00K
Free Cash Flow $560.0K $982.3K -$4.583M
YoY Change -132.22% -160.14% -19.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
21250 Hawthorne Boulevard
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Torrance
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90503
CY2019 dei City Area Code
CityAreaCode
310
CY2019 dei Local Phone Number
LocalPhoneNumber
2140065
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3905000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1788000
CY2018Q4 us-gaap Inventory Net
InventoryNet
4705000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
634000
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
16000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54852000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72571000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.30
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.97
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42259460
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36857995
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
18288000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
152000
CY2019Q4 emma Equity Method Investment
EquityMethodInvestment
13325000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
60613000
CY2018Q4 emma Equity Method Investment
EquityMethodInvestment
13569000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4474000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1761000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3267000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4079000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
720000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
332000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4364000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
241000
CY2019 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
-64000
CY2018 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
24000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6527000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3572000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
149682000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-69000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171358000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-21708000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75278000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37341393
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37341393
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16459000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4733000
CY2018Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
468000
CY2018Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
11253000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
45557000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
36222000
CY2018 us-gaap Operating Expenses
OperatingExpenses
23920000
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48987189
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2702000
CY2018 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
4476000
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
285000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
406000
CY2019Q4 us-gaap Assets
Assets
59456000
CY2018Q4 us-gaap Assets
Assets
75278000
CY2020Q2 dei Entity Public Float
EntityPublicFloat
58283977
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1769000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2150000
CY2019Q4 us-gaap Inventory Net
InventoryNet
7971000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
27929000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49343000
CY2018Q4 us-gaap Securities Borrowed
SecuritiesBorrowed
238000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1402000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
41221000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151000
CY2018Q4 us-gaap Long Term Investments
LongTermInvestments
538000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11498000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8235000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
19000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
991000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5748000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5342000
CY2019Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
600000
CY2018Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
8939000
CY2018Q4 emma Notes Payable Current Excluding Convertible Notes Payable Current
NotesPayableCurrentExcludingConvertibleNotesPayableCurrent
6212000
CY2019Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
7015000
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2995000
CY2018Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
5089000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32827000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
268000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3932000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33750000
CY2018Q4 emma Long Term Notes Payable Excluding Convertible Long Term Notes Payable
LongTermNotesPayableExcludingConvertibleLongTermNotesPayable
925000
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
5485000
CY2018Q4 us-gaap Accounts Payable Related Parties Noncurrent
AccountsPayableRelatedPartiesNoncurrent
8529000
CY2019Q4 us-gaap Liabilities
Liabilities
70509000
CY2018Q4 us-gaap Liabilities
Liabilities
96986000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
215207000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-79000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-226229000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-11053000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59456000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48471446
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48471446
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2183000
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6975000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17012000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17464000
CY2019 us-gaap Operating Expenses
OperatingExpenses
26170000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-4512000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-8454000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-438000
CY2019 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
3545000
CY2019 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
131000
CY2019 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-21947000
CY2018 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-43977000
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-414000
CY2018 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-97000
CY2019 emma Miscellaneous Reverse Merger Costs
MiscellaneousReverseMergerCosts
309000
CY2019 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
3341000
CY2019 us-gaap Interest And Other Income
InterestAndOtherIncome
232000
CY2018 us-gaap Interest And Other Income
InterestAndOtherIncome
1002000
CY2019 us-gaap Interest Expense
InterestExpense
27625000
CY2018 us-gaap Interest Expense
InterestExpense
22796000
CY2019 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-50166000
CY2018 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-64094000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54678000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72548000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
164000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
CY2019 us-gaap Profit Loss
ProfitLoss
-54842000
CY2018 us-gaap Profit Loss
ProfitLoss
-72587000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
16000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000
CY2018 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
13374000
CY2018 emma Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
18456000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1275000
CY2018 emma Stock Repurchased And Cancelled During Period Value
StockRepurchasedAndCancelledDuringPeriodValue
-5076000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4546000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-72587000
CY2019 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
8765000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8589000
CY2019 emma Stock Issued During Period Value Merger
StockIssuedDuringPeriodValueMerger
-1645000
CY2019 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
39499000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2019 emma Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
186000
CY2019 emma Warrant And Conversion Feature Reclassified To Equity
WarrantAndConversionFeatureReclassifiedToEquity
6336000
CY2019 emma Adjustments To Fair Value Of Replacement Equity Awards
AdjustmentsToFairValueOfReplacementEquityAwards
2438000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-54842000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
73000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
61000
CY2019 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
515000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
23781000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
18234000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
115000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
297000
CY2019 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-21432000
CY2018 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-43977000
CY2019 emma Share Based Compensation And Fair Value Of Replacement Equity Award
ShareBasedCompensationAndFairValueOfReplacementEquityAward
3805000
CY2018 emma Share Based Compensation And Fair Value Of Replacement Equity Award
ShareBasedCompensationAndFairValueOfReplacementEquityAward
4545000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
361000
CY2019 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-317000
CY2018 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
245000
CY2019 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
426000
CY2018 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
5312000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2451000
CY2018 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-630000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4523000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5634000
CY2019 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1645000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
221000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6439000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
94000
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
469000
CY2018 emma Payment For Capital Contributions And Loan To Equity Method Investees
PaymentForCapitalContributionsAndLoanToEquityMethodInvestees
13316000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1484000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7440000
CY2018 emma Payments For Repurchase Of Common Stock And Warrants
PaymentsForRepurchaseOfCommonStockAndWarrants
11262000
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
600000
CY2018 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
11560000
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
17816000
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
143000
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5077000
CY2019 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
5348000
CY2018 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
20000000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
186000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
111000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8589000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1275000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3884000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5577000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-13000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2136000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18651000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3905000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22556000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1769000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
1543000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
2178000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
227000
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
3000
CY2019 emma Warrant Liabilities Reclassification To Equity
WarrantLiabilitiesReclassificationToEquity
6337000
CY2018 emma Exercised Of Warrants And Options On Cashless Basis
ExercisedOfWarrantsAndOptionsOnCashlessBasis
18345000
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
33777000
CY2019 emma Conversion Of Accrued Interest Payable To Common Stock
ConversionOfAccruedInterestPayableToCommonStock
5722000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2922000
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1&#8212;DESCRIPTION OF BUSINESS</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Organization<font style="font-weight:normal;">&#8212;</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 17, 2019 Emmaus Life Sciences,&#160;Inc. (formerly, &#8220;MYnd Analytics, Inc.&#8221; and herein the &#8220;Company&#8221; or &#8220;Emmaus&#8221;) completed its merger transaction (the &#8220;Merger&#8221;) with EMI Holding, Inc., formerly known as Emmaus Life Sciences, Inc. (&#8220;EMI Holding&#8221;) a wholly owned subsidiary of the Company merged into EMI Holding, with EMI Holding surviving the Merger as a wholly owned subsidiary. Immediately after completion of the Merger, the Company changed its name to &#8220;Emmaus Life Sciences, Inc.&#8221;</p> <p style="margin-bottom:12pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger was treated as a reverse recapitalization under the acquisition method of accounting in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) For accounting purposed, EMI Holding was considered to have acquired the Company. </p> <p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with and prior to the Merger, the Company contributed and transferred to Telemynd, Inc. (&#8220;Telemynd&#8221;), a newly formed, subsidiary of the Company, all or substantially all of the Company&#8217;s historical business, assets and liabilities and the Company&#8217;s board of directors declared a stock dividend of one share of the Telemynd common stock held by the Company for each outstanding share of Company common stock after giving effect to a 1-for-6 reverse stock of the Company&#8217;s outstanding shares of common stock. The dividend, together with the contribution and transfer of the Company&#8217;s historical business, assets, and liabilities described above, is referred to as the spin-off.</p> <p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the spin-off and the Merger, the Company&#8217;s ongoing business became EMI Holding&#8217;s business, which is that of a commercial-stage biopharmaceutical company focused on the development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">References herein to the &#8220;Company&#8221; or &#8220;Emmaus&#8221; means Emmaus Life Sciences, Inc. and its direct and direct subsidiaries.</p> <p style="margin-bottom:10pt;margin-top:10pt;text-indent:7.14%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nature of Business<font style="font-weight:normal;">&#8212;The Company is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of innovative treatments and therapies, primarily for rare and orphan diseases. On July 7, 2017, the U.S. Food and Drug Administration, or FDA, approved our lead product Endari&#174; (prescription grade L-glutamine oral powder), to reduce the severe complications of sickle cell disease (&#8220;SCD&#8221;) in adult and pediatric patients five years of age and older. </font><font style="color:#000000;font-weight:normal;">Endari&#174; has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission, or EC, which designations generally afford marketing exclusivity for Endari&#174; for a seven-year period in the U.S. and for a ten-year period in the EU, respectively, following marketing approval. Endari&#174; also will be entitled to an additional two years of marketing exclusivity in the EU based on Emmaus&#8217; accepted pediatric investigation plan.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company commenced commercialization of Endari&#174; in the U.S. in January 2018 in collaboration with a contract sales organization. <font style="color:#000000;">Since January 2020, the Company has relied upon our in-house commercial sales team. Endari&#174; is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari&#174; for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. The Company has distribution agreements in place with the nation&#8217;s leading distributors, as well as physician group purchasing organizations and pharmacy benefits managers, making Endari&#174; available at selected pharmacies nationwide.</font><font style="font-size:12pt;"> </font>Prior to 2018,<font style="font-size:12pt;"> </font>the Company had minimal revenues and relied upon funding from sales of equity securities and debt financings and loans, including loans from related parties to fund our business and operations.</p> <p style="margin-bottom:0pt;margin-top:14pt;text-indent:7.14%;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 4, 2018, the FDA acknowledged receipt of the Company&#8217;s investigational new drug application, or IND, for the treatment of diverticulosis using the same prescription-grade L-glutamine oral powder used in Endari<font style="color:#000000;">&#174;</font>. The Company subsequently received a &#8220;Study May Proceed&#8221; letter from the FDA, and in July 2019 the Company successfully enrolled 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> subject in a Pilot/Phase 1 study of the safety and efficacy of prescription-grade L-glutamine oral powder and expects to enroll 10 to 15 patients at multiple study sites. The study will evaluate the change in the number and size of colonic diverticula and assess safety.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimates<font style="font-weight:normal;">&#8212;Financial statements prepared in accordance with GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant assumptions made by management include those relating to revenue recognition on product sales, the estimated useful lives of equipment, impairment of assets, the variables used to calculate the valuation of conversion features, stock options and warrants, and estimated accruals on an ongoing basis. The Company&#8217; base&#8217;s its estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates under different assumptions or conditions. To the extent there are material differences between these estimates and actuals, the Company&#8217;s financial statements will be affected.</font></p>
CY2019 emma Number Of Vendors
NumberOfVendors
1
CY2018 emma Number Of Vendors
NumberOfVendors
1
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2018 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
12933664
CY2018 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
17406715
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2018 emma Interest And Other Income Loss
InterestAndOtherIncomeLoss
1002000
CY2018 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-72571000
CY2018 emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
2560000
CY2018 emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
1579000
CY2018Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
981000
CY2019 emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
4691000
CY2019 emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
3775000
CY2019Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
1897000
CY2019Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
1145000
CY2018Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
171000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2187000
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2471000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4639000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2063000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
735000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
223000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
667000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
411000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
507000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
455000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
356000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
303000
CY2019 us-gaap Depreciation
Depreciation
59000
CY2018 us-gaap Depreciation
Depreciation
47000
CY2018 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
27929000
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
49581000
CY2018Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
538000
CY2019 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-21400000
CY2018 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-43200000
CY2019Q4 us-gaap Equity Method Investment Summarized Financial Information Current Assets
EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets
2310000
CY2018Q4 us-gaap Equity Method Investment Summarized Financial Information Current Assets
EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets
13505000
CY2019Q4 emma Equity Method Investment Summarized Financial Information Other Assets
EquityMethodInvestmentSummarizedFinancialInformationOtherAssets
10654000
CY2019Q4 us-gaap Equity Method Investment Summarized Financial Information Assets
EquityMethodInvestmentSummarizedFinancialInformationAssets
12964000
CY2018Q4 us-gaap Equity Method Investment Summarized Financial Information Assets
EquityMethodInvestmentSummarizedFinancialInformationAssets
13505000
CY2019Q4 us-gaap Equity Method Investment Summarized Financial Information Current Liabilities
EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities
296000
CY2018Q4 us-gaap Equity Method Investment Summarized Financial Information Current Liabilities
EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities
33000
CY2019Q4 us-gaap Equity Method Investment Summarized Financial Information Noncurrent Liabilities
EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities
13870000
CY2018Q4 us-gaap Equity Method Investment Summarized Financial Information Noncurrent Liabilities
EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities
13634000
CY2019Q4 us-gaap Equity Method Investment Summarized Financial Information Liabilities
EquityMethodInvestmentSummarizedFinancialInformationLiabilities
14166000
CY2018Q4 us-gaap Equity Method Investment Summarized Financial Information Liabilities
EquityMethodInvestmentSummarizedFinancialInformationLiabilities
13667000
CY2019Q4 us-gaap Equity Method Investment Summarized Financial Information Minority Interest
EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest
-721000
CY2018Q4 us-gaap Equity Method Investment Summarized Financial Information Minority Interest
EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest
-97000
CY2019 us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
229000
CY2018 us-gaap Equity Method Investment Summarized Financial Information Revenue
EquityMethodInvestmentSummarizedFinancialInformationRevenue
57000
CY2019 us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
-1035000
CY2018 us-gaap Equity Method Investment Summarized Financial Information Net Income Loss
EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
-243000
CY2019Q4 emma Cro Expenses
CROExpenses
232000
CY2018Q4 emma Cro Expenses
CROExpenses
83000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1183000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2157000
CY2019Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
1303000
CY2018Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
382000
CY2019Q2 us-gaap Share Price
SharePrice
10.30
CY2018Q3 us-gaap Share Price
SharePrice
11.10
CY2018Q3 us-gaap Share Price
SharePrice
11.30
CY2018Q1 us-gaap Share Price
SharePrice
11.40
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
10.30
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
11.10
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
11.30
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
11.40
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0183
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0299
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0288
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0275
CY2019Q4 emma Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
4541000
CY2019Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
18000
CY2018Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
844000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7277000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3466000
CY2019Q4 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
42000
CY2018Q4 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
842000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
991000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2138000
CY2019Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
891000
CY2018Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
713000
CY2019Q4 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
1355000
CY2018Q4 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
933000
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
238000
CY2018Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
57000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
704000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
86000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3188000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1789000
CY2019Q4 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
17142000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3190000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
13952000
CY2019 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
1444291
CY2018Q4 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
55172000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
17211000
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
37961000
CY2018 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
6496892
CY2019Q4 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.10
CY2018Q4 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.10
CY2019Q4 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.66
CY2018Q4 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.35
CY2019Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
10.00
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4931099
CY2019Q4 emma Warrants Exercisable
WarrantsExercisable
4931099
CY2019Q4 emma Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Permitted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPermitted
12
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6716
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6914
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6609
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6818
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6340000
CY2019 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
5710000
CY2018 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
4130000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
545000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
431000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
3619000
CY2018Q4 emma Deferred Tax Liabilities Unrealized Currency Transaction Loss And Others
DeferredTaxLiabilitiesUnrealizedCurrencyTransactionLossAndOthers
176000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
4000
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
2000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
189000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3143000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3800000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
20800000
CY2019Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
9900000
CY2018Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
9300000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11365000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-15195000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-666000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3695000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3411000
CY2019Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
81000
CY2018Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
139000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
166000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
364000
CY2019Q4 emma Deferred Tax Assets Unearned Revenue
DeferredTaxAssetsUnearnedRevenue
175000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
164000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
38000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16773000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19573000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
9888000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
9342000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5723000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5997000
CY2018Q4 emma Deferred Tax Assets Unearned Revenue
DeferredTaxAssetsUnearnedRevenue
1396000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
2373000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
173000
CY2019Q4 emma Deferred Tax Assets Unrealized Gain Loss On Long Term Investment
DeferredTaxAssetsUnrealizedGainLossOnLongTermInvestment
1400000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1629000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
352000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38208000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
37336000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38019000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
34193000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
189000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3143000
CY2018Q4 emma Deferred Tax Liabilities Unrealized Loss On Long Term Investments
DeferredTaxLiabilitiesUnrealizedLossOnLongTermInvestments
2965000
CY2019Q4 emma Deferred Tax Liabilities Unrealized Currency Transaction Loss And Others
DeferredTaxLiabilitiesUnrealizedCurrencyTransactionLossAndOthers
185000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
8890000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
926000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
669000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
991000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1080000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1110000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1043000
CY2019Q4 emma Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
2983000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7207000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2284000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4923000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y1M6D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.118
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
730000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
974000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
973000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1003000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
3665000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7345000
CY2018 emma Description On Debt Instrument Term
DescriptionOnDebtInstrumentTerm
Non Current, Convertible notes payable to related parties:
CY2019Q4 emma Convertible Debentures Conversion Price
ConvertibleDebenturesConversionPrice
9.52
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.87
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1326000
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1982000
CY2019Q3 us-gaap Inventory Net
InventoryNet
7491000
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
27643000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1541000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
39983000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163000
CY2019Q3 emma Equity Method Investment
EquityMethodInvestment
13407000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4118000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
427000
CY2019Q3 us-gaap Assets
Assets
58098000
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10926000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
844000
CY2019Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6033000
CY2019Q3 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
91000
CY2019Q3 emma Notes Payable Current Excluding Convertible Notes Payable Current
NotesPayableCurrentExcludingConvertibleNotesPayableCurrent
3886000
CY2019Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
193000
CY2019Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
6470000
CY2019Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2928000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
31371000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3714000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34556000
CY2019Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
706000
CY2019Q3 us-gaap Liabilities
Liabilities
70347000
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
48000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
212619000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-51000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-224865000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-12249000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58098000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47671446
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47671446
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5760000
CY2019Q3 emma Miscellaneous Reverse Merger Costs
MiscellaneousReverseMergerCosts
309000
CY2019Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
3341000
CY2019Q3 emma Interest And Other Income Loss
InterestAndOtherIncomeLoss
18000
CY2019Q3 us-gaap Interest Expense
InterestExpense
8714000
CY2019Q3 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-14289000
us-gaap Interest Expense
InterestExpense
25153000
emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-48025000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53237000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
241000
us-gaap Profit Loss
ProfitLoss
-53478000
us-gaap Net Income Loss
NetIncomeLoss
-53478000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
18000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
18000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
248000
CY2019Q3 us-gaap Gross Profit
GrossProfit
5512000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
725000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1778000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7056000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
9559000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4047000
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-438000
CY2019Q3 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
3576000
CY2019Q3 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
131000
CY2019Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-5248000
CY2019Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
36000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18336000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-18361000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-18361000
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-18356000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18356000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45986629
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15960000
us-gaap Cost Of Revenue
CostOfRevenue
771000
us-gaap Gross Profit
GrossProfit
15189000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1778000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5148000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13475000
us-gaap Operating Expenses
OperatingExpenses
20401000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5212000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-438000
emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
3492000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
131000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-22242000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-413000
emma Miscellaneous Reverse Merger Costs
MiscellaneousReverseMergerCosts
309000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
3341000
emma Interest And Other Income Loss
InterestAndOtherIncomeLoss
248000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-53460000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53460000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.32
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40443124
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
524000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
21875000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
207000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-21718000
emma Share Based Compensation And Fair Value Of Replacement Equity Award
ShareBasedCompensationAndFairValueOfReplacementEquityAward
3593000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
193000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2787000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1025000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4150000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5966000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
500000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-287000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
828000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2363000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4137000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1641000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
221000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1475000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
3368000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
186000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6210000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3028000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2579000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1326000
us-gaap Interest Paid Net
InterestPaidNet
1239000
us-gaap Income Taxes Paid
IncomeTaxesPaid
242000
emma Warrant Liabilities Reclassification To Equity
WarrantLiabilitiesReclassificationToEquity
6337000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
33777000
emma Conversion Of Accrued Interest Payable To Common Stock
ConversionOfAccruedInterestPayableToCommonStock
2381000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2922000

Files In Submission

Name View Source Status
0001564590-21-001977-index-headers.html Edgar Link pending
0001564590-21-001977-index.html Edgar Link pending
0001564590-21-001977.txt Edgar Link pending
0001564590-21-001977-xbrl.zip Edgar Link pending
emma-10k_20191231.htm Edgar Link pending
emma-20191231.xml Edgar Link completed
emma-20191231.xsd Edgar Link pending
emma-20191231_cal.xml Edgar Link unprocessable
emma-20191231_def.xml Edgar Link unprocessable
emma-20191231_lab.xml Edgar Link unprocessable
emma-20191231_pre.xml Edgar Link unprocessable
emma-ex1011_7.htm Edgar Link pending
emma-ex1012_10.htm Edgar Link pending
emma-ex1023_941.htm Edgar Link pending
emma-ex1025_1511.htm Edgar Link pending
emma-ex1026_1513.htm Edgar Link pending
emma-ex1027_3369.htm Edgar Link pending
emma-ex1028_3370.htm Edgar Link pending
emma-ex1029_3371.htm Edgar Link pending
emma-ex1030_940.htm Edgar Link pending
emma-ex1033_303.htm Edgar Link pending
emma-ex1034_1159.htm Edgar Link pending
emma-ex1035_1160.htm Edgar Link pending
emma-ex1037_1629.htm Edgar Link pending
emma-ex211_14.htm Edgar Link pending
emma-ex311_11.htm Edgar Link pending
emma-ex312_6.htm Edgar Link pending
emma-ex31_12.htm Edgar Link pending
emma-ex321_13.htm Edgar Link pending
emma-ex41_15.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g43jxiasw2qp000001.jpg Edgar Link pending
gdpuocnnxw5f000001.jpg Edgar Link pending
gdpuocnnxw5f000002.jpg Edgar Link pending
gejyikyqeztn000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending